BCL2 and cancer: As NF-κB binding sites have been identified in the promoters of Bcl-2, Bcl-xL, and survivin [45,338,339,340,341,342,343], it is suggested that genistein may inhibit their expression through NF-κB downregulation, thereby sensitizing cancer cells to apoptosis induced by docetaxel, cisplatin, or doxorubicin.